Reports
As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market: By Indication: Lung Cancer, Colorectal Cancer, Breast Cancer; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; SWOT Analysis; Porter’s Five Forces Analysis; Competitive Landscape; Industry Events and Developments
Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook
The global epidermal growth factor receptor (EGFR) inhibitors market is projected to grow at a CAGR of 8.6% during the forecast period of 2022-2027.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The growing incidences of cancer globally, along with the increasing geriatric population and lifestyle changes are some of the major drivers for the industry growth. Epidermal growth factor inhibitors (EGFRI) is the first targeted cancer therapy, which has become an essential treatment for many advance-stage epithelial cancers. In comparison to conventional chemotherapies, these agents have the superior ability to target cancer cells, further offering better safety profile to the patients.
Properties and Applications
Epidermal growth factor receptor (EGFR) inhibitors are medicines that slow down or stop EGFR’s activity, a protein found on the surface of some normal cells, by binding to its certain part. EGFR or epidermal growth factor receptor causes cells to divide upon binding to it by signalling pathways that control cell division and survival, leading to the growth of normal cells. Certain mutations in EGFR are known to be vulnerable and can lead to the growth of cancer cells.
The global epidermal growth factor receptor (EGFR) inhibitors industry can be divided based on segments like indication and region.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on indication, the industry can be segmented into:
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Others
The EMR report looks into the regional epidermal growth factor receptor (EGFR) markets like North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
The global epidermal growth factor receptor inhibitors industry is being supported by the increase in the number of cancer cases such as lung cancer, colorectal cancer, breast cancer, and others. The growing incidences of cancer throughout the world also calls for more efficient therapy techniques that encourage scientists to create EGFR antibodies. Because of the busy lifestyle, excessive alcohol consumption and smoking habits, the incidence of cancer is quickly growing, particularly in regions like North America and Europe. The increasing morbidity and mortality rates among patients with cancer are leading to enhanced demand for EGFR antibodies, thus driving the market forward. Due to an enormous unmet need for new therapies to treat cancer symptoms, several pharmaceutical companies are focusing on the development of advanced EGFR inhibitors to capitalise on this enormous unmet need, which is expected to aid the industry over the forecast period.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global epidermal growth factor receptor (EGFR) inhibitors market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Amgen Inc. (NASDAQ: AMGN)
- AstraZeneca
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2017-2021 |
| Forecast Period | 2022-2027 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Indication, Region |
| Breakup by Indication | Lung cancer, Colorectal cancer, Breast cancer, Others |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Amgen Inc. (NASDAQ: AMGN), AstraZeneca (LON: AZN), Eli Lilly and Company (NYSE: LLY), F. Hoffmann-La Roche Ltd. (SWX: ROG), Novartis AG (SWX: NOVN), Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.1.1 Research Objective
1.1.2 Key Findings of the Report
2 Research Methodology
2.1 Data Extraction
2.2 Data Corroboration
2.3 Market Structure
2.4 Assumptions
2.5 Market Models
3 Introduction
3.1 Market Outlook
3.2 Market Scope and Segmentation
3.3 Additional Insights
4 Executive Summary
4.1 Key Market Developments
4.2 Market Analysis
4.3 Key Players
4.4 Cost Structure
4.5 Market Revenue and Growth
5 Market Dynamics
5.1 Market Driver Analysis
5.2 Market Restraint Analysis
5.3 Industry Challenges
5.4 Industry Opportunities
6 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Analysis
6.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market (2017-2021) & Forecast (2022-2027)
6.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Breakup by Indication
6.2.1 Lung cancer
6.2.2 Colorectal cancer
6.2.3 Breast cancer
6.2.4 Others
6.3 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Breakup by Indication: Historical Market (2017-2021) & Forecast (2022-2027)
6.3.1 Lung cancer
6.3.2 Colorectal cancer
6.3.3 Breast cancer
6.3.4 Others
6.4 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Breakup by Region
6.4.1 North America
6.4.1.1 United States of America
6.4.1.2 Canada
6.4.2 Europe
6.4.2.1 Germany
6.4.2.2 United Kingdom
6.4.2.3 France
6.4.2.4 Italy
6.4.2.5 Others
6.4.3 Asia Pacific
6.4.3.1 China
6.4.3.2 Japan
6.4.3.3 India
6.4.3.4 ASEAN
6.4.3.5 Others
6.4.4 Latin America
6.4.4.1 Brazil
6.4.4.2 Argentina
6.4.4.3 Mexico
6.4.4.4 Others
6.4.5 Middle East & Africa
6.4.5.1 Saudi Arabia
6.4.5.2 United Arab Emirates
6.4.5.3 Nigeria
6.4.5.4 South Africa
6.4.5.5 Others
6.5 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Breakup by Region: Historical Market (2017-2021) & Forecast (2022-2027)
6.5.1 North America
6.5.1.1 United States of America
6.5.1.2 Canada
6.5.2 Europe
6.5.2.1 Germany
6.5.2.2 United Kingdom
6.5.2.3 France
6.5.2.4 Italy
6.5.2.5 Others
6.5.3 Asia Pacific
6.5.3.1 China
6.5.3.2 Japan
6.5.3.3 India
6.5.3.4 ASEAN
6.5.3.5 Others
6.5.4 Latin America
6.5.4.1 Brazil
6.5.4.2 Argentina
6.5.4.3 Mexico
6.5.4.4 Others
6.5.5 Middle East & Africa
6.5.5.1 Saudi Arabia
6.5.5.2 United Arab Emirates
6.5.5.3 Nigeria
6.5.5.4 South Africa
6.5.5.5 Others
7 SWOT Analysis
7.1 Overview
7.2 Strengths
7.3 Weaknesses
7.4 Opportunities
7.5 Threats
8 Porter’s Five Forces Analysis
8.1 Overview
8.2 Buyer’s Power
8.3 Supplier’s Power
8.4 New Entrants
8.5 Degree of Rivalry
8.6 Substitutes
9 Competitive Landscape & Supplier Analysis
9.1 Amgen Inc. (NASDAQ: AMGN)
9.1.1 Company Overview
9.1.2 Financial Analysis
9.2 AstraZeneca (LON: AZN)
9.2.1 Company Overview
9.2.2 Financial Analysis
9.3 Eli Lilly and Company (NYSE: LLY)
9.3.1 Company Overview
9.3.2 Financial Analysis
9.4 F. Hoffmann-La Roche Ltd. (SWX: ROG)
9.4.1 Company Overview
9.4.2 Financial Analysis
9.5 Novartis AG (SWX: NOVN)
9.5.1 Company Overview
9.5.2 Financial Analysis
9.6 Others
10 Industry Events and Developments
Key Questions Answered in the Report
The global epidermal growth factor receptor (EGFR) inhibitors market is projected to grow at a CAGR of nearly 8.6% in the forecast period of 2022-2027.
The major drivers of the industry include rising disposable incomes, increasing population, rising cases of cancer, increasing geriatric population, and the rising lifestyle changes.
The increasing cancer-related morbidity and mortality rates are expected to be the key trends guiding the growth of the industry.
North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa are the leading regions in the market.
The leading indication segments in the industry include lung, colorectal, and breast cancer, among others.
The leading players in the market are Amgen Inc., AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Novartis AG, among others.
Analyst Review
The global epidermal growth factor receptor (EGFR) inhibitors market was driven by the rising cases of cancer. Aided by the changing lifestyles, the industry is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 8.6%.
EMR’s meticulous research methodology delves deep into the industry, covering the macro and micro aspects of the industry. Based on indication, the market can be segmented into lung, colorectal, and breast cancer, among others. The major regional markets for epidermal growth factor receptor (EGFR) inhibitors are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above industry include Amgen Inc., AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Novartis AG, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?RIGHT PEOPLE
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
RIGHT METHODOLOGY
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
RIGHT PRICE
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
RIGHT SUPPORT
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The global thrombin market attained a value of more than USD 578.5 million in 2021, driven by the rising cases of haemophilia. Aided by the technological advancements in the healthcare industry in the...
The global transcatheter pulmonary valve market is expected to grow at a CAGR of 7.4% during the period 2022-2027.
The global PD-1 and PD-L1 inhibitors market attained a value of USD 30.3 billion in 2021, driven by the rising incidences of cancer. Aided by the growing geriatric population and favourable government...
The global biosurgery market attained a value of more than USD 13.4 billion in 2021, driven by the prevalence of different biosurgeries. Aided by advancements in healthcare structure, the market is ex...
The global albumin market attained a value of USD 5.3 billion in 2021, driven by the rising benefits of HSA on commercial and therapeutic applications. Aided by advancements in nanotechnology for drug...
NEWSLETTER